OneSource Specialty Pharma Releases Unaudited Consolidated Financial Results for Quarter Ended June 30, 2026
Onesource Specialty Pharma Limited has released its Unaudited Consolidated Financial Results for the quarter ended June 30, 2026. These results include the financial information of several entities within the group structure.The Statement of Unaudited Consolidated Financial Results comprises data from seven entities. This includes:
| Sl. No. | Name of the Entities |
|---|---|
| 1 | OneSource Specialty Pharma Limited, the Parent |
| 2 | OneSource Specialty PTE. Limited, wholly owned subsidiary |
| 3 | Strides Pharma Services Private Limited, wholly owned subsidiary |
| 4 | Biolexis Private Limited, wholly owned subsidiary |
| 5 | OneSource Specialty Pharma Inc, wholly owned subsidiary |
| 6 | OneSource Softgels PTE. Ltd., step-down subsidiary |
| 7 | Biolexis PTE. Ltd, step-down subsidiary |
Status of Reviewed Subsidiaries
The results include two subsidiaries whose interim financial information was reviewed by other auditors. This group reported total revenues of Rs. 283.47 million for the quarter ended June 30, 2026. Furthermore, these entities recorded a total net loss after tax of Rs. 12.14 million and an other comprehensive income of Rs. 12.44 million for the same period.
Unaudited Entities Included in Results
Additionally, the Unaudited Consolidated Financial Results incorporate data from four subsidiaries that were not reviewed or audited by their respective auditors during this period. For these entities, the interim financial information reflected total revenue of Rs. Nil for the quarter ended June 30, 2026. They recorded a total loss after tax of Rs. 1.79 million and an other comprehensive income of Rs. Nil as reflected in the Statement. Management confirmed that this interim financial information was not material to the Group.
ONESOURCE Stock Price Movement
Shares of Onesource Specialty Pharma Limited today slipped by 0.32% to settle at ₹1653.90 in post-market trading. The stock saw a total traded volume of 87,251 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.